Detalhe da pesquisa
1.
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.
Invest New Drugs
; 42(1): 44-52, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38055127
2.
Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer.
Eur J Clin Pharmacol
; 79(3): 407-414, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36645467
3.
Comparative trial of two intravenous doses of granisetron (1 versus 3 mg) in the prevention of chemotherapy-induced acute emesis: a double-blind, randomized, non-inferiority trial.
Support Care Cancer
; 20(5): 1057-64, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21590327
4.
A retrospective study comparing interventions by oncology and non-oncology pharmacists in outpatient chemotherapy.
Cancer Rep (Hoboken)
; 4(4): e1371, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33739629
5.
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Gan To Kagaku Ryoho
; 37(7): 1307-11, 2010 Jul.
Artigo
Japonês
| MEDLINE | ID: mdl-20647715
6.
[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
Gan To Kagaku Ryoho
; 36(10): 1697-702, 2009 Oct.
Artigo
Japonês
| MEDLINE | ID: mdl-19838030